Rare disorder focus Target pharmaceutical buyers and clinicians serving rare bleeding disorders, including hemophilia A or B with inhibitors, to introduce specialized, plasma-based and recombinant therapies aligned with HEMA Biologics’ niche focus.

North America expansion Emphasize opportunities to broaden access in the U.S. market by partnering with rare disease networks, hemophilia treatment centers, and payer programs, leveraging the heritage of LFB for credibility in ultrapure plasma-based products.

Strategic partnerships Position as a gateway for collaborations with contract manufacturers, CROs, and biotech distributors who value a focused, patient-centric pipeline, aiming to accelerate development and distribution of hemophilia with inhibitors therapies.

Mid-market potential Highlight the company’s revenue range and scaled resources to target mid-sized biopharma buyers and specialty distributors seeking niche, high-value products in rare bleeding disorders with clear clinical impact.

Digital and credibility Leverage the company’s LFB-backed heritage and current tech stack to build trust with stakeholders; deploy targeted digital outreach to hematologists, transfusion medicine specialists, and patient advocacy groups to generate early interest and partnerships.